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The immunophenotypes of these subtypes are listed in Table 1 ETP ALL were originally described as a high-risk group associated with poor response to therapy and dismal prognosis; however, this group seems to be heterogeneous and not always associated with poor prognosis (Litzow and Ferrando, 2015).
Molecular landscape of T-ALL
In 1991, Ellisen et al. identified a t(7;9)(q34;q34.4) translocation in T-ALL patients, which resulted in fusion of the 3` region of NOTCH1 into the TCR-β locus and consequent overexpression of the active form of Notch1 (ICN1). This translocation appeared to be rare, found in <1% of T-ALL cases. However, 13 
Treatment of older adults with T-ALL
The hyper-CVAD (cyclophosphamide, vincristine, Adriamycin, and dexamethasone alternating with high dose methotrexate and cytarabine) regimen is considered intensive and in spite of this is reasonably well tolerated in fit older individuals. However, in a small series of T-ALL patients, although a high CR rate was seen with the hyper-CVAD regimen, and it was safely administered, there was 
Gamma secretase inhibitors (GSI)
The high 
Tyrosine kinase inhibitors, do they have a role?
The NUP214-ABL1 gene is the second most prevalent fusion gene involving ABL1 in malignant hemopathies, with a frequency of 5% in T-cell ALL 
Monoclonal antibodies in T-ALL: Do they have a role?
For patients with T-ALL, the development of T cell-directed monoclonal antibody therapies are lagging compared with B-ALL. Alemtuzumab is a humanized monoclonal antibody against CD52. CD52 is expressed in 36% to 66% of leukemia cases, including B-and T-ALL and acute myeloid leukemia.
Alemtuzumab has been investigated in small trials, but its development has been slow because of its modest activity and significant side effects. In 1 series, 3
children with relapsed T-ALL received alemtuzumab; none responded ( 
